Since the advent of transcatheter aortic valve replacement, the multidisciplinary heart team (MHT) approach has rapidly become the standard of care for patients undergoing the procedure. However, little is known about the potential effect of MHT on patients with coronary artery disease (CAD).
T he concept of a multidisciplinary care team is not new within the field of medicine. The concept is well established in the fields of oncology and solid-organ transplantation. 1, 2 Within cardiovascular medicine, it is an established entity in the management of heart failure 3,4 and congenital heart disease 5, 6 in the pediatric and adult populations and is becoming the standard of care in randomized clinical trials involving complex cardiac conditions. [7] [8] [9] Within the subspecialty of coronary revascularization, during the conduct of randomized clinical trials, a dedicated multidisciplinary heart team (MHT) has been used successfully. 10, 11 Despite the successful implementation in randomized clinical trials and the recommendation of the latest practice guidelines that the MHT approach be incorporated into clinical practice, the current literature suggests that decision making regarding treatment modalities in patients with coronary artery disease (CAD) is often not based on empirical evidence and is subject to operator bias. In a review of New York cardiac catheterization registry data for patients who met indications for coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), 93% were referred for PCI, 2% for medical management, and only 5% for CABG.
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With this issue in mind, MHT cooperation should provide a balanced approach toward designing the optimal revascularization strategy for a given patient, taking into account patient preference, coronary anatomy, and clinical comorbidities. Implementation of the MHT approach creates transparency, ensures appropriate adherence to established societal guidelines, and provides the most objective recommendations while minimizing the influence of individual biases. The approach provides a way for cardiac surgeons and cardiologists to share the burden of decision making and outcomes. Such collaboration fosters an environment of teamwork, collegiality, and bidirectional exchange of knowledge that benefits all involved parties but most importantly the patient. Despite these benefits, the exact nature of the safety and benefits of the MHT approach for coronary revascularization requires further study and description.
In an effort to provide an individualized and unbiased approach to complex coronary disease, we instituted an MHT in May 2012 at the Heart and Vascular Institute of the University of Pittsburgh Medical Center, Presbyterian Hospital. Within this structured format, a previous report 13 demonstrated successful feasibility of implementing an MHT approach for patients with complex coronary disease. The aims of our present study are to demonstrate the safety and efficacy of the MHT approach for patients with complex CAD and to evaluate the midterm outcomes of these patients in an observational cohort study.
Methods

Patient Population
This study was approved by the institutional review board of the University of Pittsburgh Medical Center, and informed consent was waived. From May 1, 2012, to May 31, 2013, all patients who underwent left-sided heart catheterization and met the following criteria were included in the study: (1) unprotected left main CAD; (2) 3-vessel CAD; (3) 2-vessel CAD involving the proximal left anterior descending artery; (4) CAD in the proximal left anterior descending artery in patients with diabetes mellitus; and (5) any other complex CAD in which the initial treating physician believed that revascularization could be performed reasonably using a percutaneous or a surgical approach.
Exposure
Since May of 2012, MHT meetings were convened each business weekday at 7 AM to include a board-certified attending physician from various specialties. At a minimum, cardiac surgery and intervention cardiology were represented. Details of the MHT structure and its implementation have been described previously 13 and include detailed patient history, risk factors, frailty, review of coronary angiograms, and calculation of important risk scores, such as the SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score and the Society of Thoracic Surgeons risk score for mortality and morbidity. 14 The MHT recommendation was adjudicated with the appropriateness for coronary revascularization based on the appropriate use criteria for revascularization and individual patient comorbidities. 14 Novel innovative approaches to coronary revascularization, such as hybrid procedures involving minimally invasive CABG followed by staged PCI during the same hospitalization, were discussed during the MHT meeting when anatomically feasible and adjudicated on an individual case basis after thorough discussion with the patient regarding the advantages and disadvantages of the hybrid procedure vs other standard therapeutic options.
Outcome Measures
The safety and efficacy of MHT were evaluated by 30-day periprocedural mortality and midterm major adverse cardiac cerebrovascular events during the median follow-up of 12.1 months. Major adverse cardiac cerebrovascular events were defined as death from any cause, the need for a second myocardial revascularization, myocardial infarction, congestive heart failure, angina, or stroke. Electronic medical records of each patient were reviewed manually.
Results
A total of 180 patients were included in this pilot study. (Table) . Not surprisingly, patients for whom maximum medical therapy was recommended tended to have more complex coronary artery lesions and lower ejection fractions and to be older. Patients with a significantly elevated predicted preoperative risk for mortality according to the Society of Thoracic Surgeons criteria 14 were usually adjudicated to undergo PCI or medical therapy alone for their complex CAD. The 30-day mortality rate for the study cohort ranged from 0 to 12% (Figure 1) . During the median follow-up of 12.1 months, the incidence of major adverse cardiac cerebrovascular events for the study cohort ranged from 0 to 23% (Figure 2 ). established standard of care for evaluation and treatment of patients who need transcatheter valvular intervention. [7] [8] [9] [16] [17] [18] Despite the preponderance of evidence of improved clinical outcomes in other medical and surgical specialties, [1] [2] [3] [4] [5] [6] [7] [8] [9] 15 an MHT approach to CAD has not been well accepted or well established. The reasons may be partly owing to logistic and/or financial incentives but may also be related to the lack of clinical data on how a real-world coronary revascularization heart team influences management decisions. One of the initiatives of our newly established University of Pittsburgh Medical Center Heart and Vascular Institute (which includes cardiology, cardiac surgery, and vascular specialists) is to provide optimal evidence-based care for patients with cardiac disease. As a result, based on the merits of MHT in transcatheter aortic valve replacement programs, a previous investigation 13 was able to show successful novel implementation of an MHT for patients with complex CAD. In the present study, we further examined the safety and efficacy of this pilot program, specifically looking at midterm outcomes. We were able to demonstrate acceptable outcomes for patients with complex CAD using the MHT approach. The clinical outcomes of this pilot MHT program for CAD were similar to those historically published in the literature as evidenced by recent systematic reviews. 19 Given the paucity of outcome data on the MHT approach to CAD, our study represents, to our knowledge, one of the first pilot programs to examine the safety and efficacy of such a standardized method. The relatively high mortality rate in the PCI group is related to the highrisk nature of this cohort. The mortality largely occurred in patients who required hemodynamic support for PCI, and their high risk is further reflected by their relatively high Society of Thoracic Surgeons mortality risk score. Because treatment plans were all individualized based on each patient's unique presentation, comorbidities, complexity of CAD, and evidence-based guidelines, we are not surprised that our findings demonstrated the safety and efficacy of such a novel MHT program for CAD. The next step in evaluating our pilot MHT program is to examine whether the MHT approach provides a more cost-efficient model for patients with CAD compared with the usual-care model. Our findings not only provide evidence favoring continuation of the MHT program for complex CAD but also provide data to initiate future prospective randomized clinical trials to determine whether an MHT program improves patient outcomes in complex CAD.
As with any new initiative, the implementation of an MHT approach for complex CAD in our institution was met with some initial barriers and obstacles that we have overcome. 13 Two of the most notable challenges were determining the appropriate time for the MHT meeting and obtaining the commitment from various specialties to participate in the meeting. Because of the multidisciplinary nature of the program, numerous competing inter- Patients undergoing a hybrid procedure (CABG followed by staged PCI) were excluded from the analysis because they were difficult to classify.
ests and schedules from various specialists make it somewhat difficult to have a recurring meeting time that will work for everyone involved. Real-time communication of patient information to numerous specialists for coordinating MHT care was also a big challenge that was overcome by using the University of Pittsburgh Medical Center internal encrypted e-mail system along with smart phones for individual physicians. Ultimately, the most critical acceptance and participation needed to come from key leaders of cardiology and cardiac surgery. Once the departments agreed, commitment from individual physicians naturally fell into place. Some limitations to this observational cohort study must be acknowledged. The primary focus of the study is the relative safety and efficacy of the pilot MHT program overall for patients with CAD, so it was not powered to detect outcome differences on a specific CAD treatment modality (ie, PCI, CABG, hybrid, or medical therapy alone). Nevertheless, the safety and efficacy of such an MHT program was established based on our midterm outcomes data when compared with historical controls. 19 In addition, our results may not be generalizable because of the relatively small number of patients in our study, and we did not have mechanisms in place that capture the real-time decision-making process in MHT meetings. With longer follow-up and continual recruitment of patients in the MHT program, we believe further data will support a generalized use of MHT for patients with complex CAD.
Conclusions
Our investigative team has demonstrated successful feasibility 13 and established the relative safety and efficacy of an MHT approach for patients with CAD. Through leadership commitment from cardiology and cardiac surgery clinicians, a programmatic MHT approach can improve the delivery of quality evidence-based care in complex CAD. Future directions for our investigative team will include comparative effective analysis to further determine whether the MHT model will improve efficiency and perhaps patient satisfaction.
